Saturday, 31 October 2026European Markets
ExploreSearch
ViaNews EU

European Financial Services

3 articles

Victory Capital's $2.1B Janus Henderson Bid Tests European Asset Management Scale Rules

Victory Capital's $2.1B Janus Henderson Bid Tests European Asset Management Scale Rules

Victory Capital's February 26 acquisition offer for Janus Henderson puts the UK-listed manager's European operations under US ownership scrutiny. The deal reflects asset management consolidation as fee compression forces scale requirements while Janus Henderson's European subsidiaries face MiFID II and AIFMD compliance reviews under new ownership.

ViaNews Editorial Team (Europe)•
HSBC and Hiscox drive European insurance sector gains with capital deployment strategies

HSBC and Hiscox drive European insurance sector gains with capital deployment strategies

European insurers HSBC and Hiscox are leading sector performance through strategic capital market activities and operational refinancing. The moves come as insurance and banking conglomerates report robust earnings growth, with automation initiatives saving over 200,000 hours across three years while maintaining flat headcount despite business expansion.

ViaNews Editorial Team (Europe)•
Goldman Sachs exits consumer banking after $4B in losses, refocuses on institutional finance

Goldman Sachs exits consumer banking after $4B in losses, refocuses on institutional finance

Goldman Sachs has sold its Marcus loan portfolio, GreenSky platform, and Personal Financial Management unit while offloading the Apple Card program to JPMorgan by 2026. The Wall Street bank absorbed roughly $4 billion in consumer banking losses before pivoting to institutional finance through its new Capital Solutions Group and acquisitions of Industry Ventures and Innovator Capital Management in 2025.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com